Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying
Profil Institut für Stoffwechselforschung GmbH · Diabetes Mellitus
Phase 2
Completed
39
2015-01
Industry sponsor intelligence
Profil Institut für Stoffwechselforschung GmbHClinical Pipeline.
Lead-sponsor view of Profil Institut für Stoffwechselforschung GmbH's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 2
- Recruiting
- 0
- Active
- 0
- Completed
- 1
- Results posted
- 0
- Avg enrollment
- 74
Pipeline overview
Programs by phase and activity.
Velocity
Profil Institut für Stoffwechselforschung GmbH trials by start year
Study start year · indexed snapshot
Development
Trials by phase
2phase labels
Early Phase 10
Phase 11
Phase 21
Phase 30
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Lixisenatide → | 2 | 1 | 1 | 0 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Search sponsor records
All Profil Institut für Stoffwechselforschung GmbH studies.
This page groups studies where Profil Institut für Stoffwechselforschung GmbH is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
2 matching studies
Last registry update first
Recent updates